(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.32%.
Quince Therapeutics's earnings in 2026 is -$33,037,000.On average, 4 Wall Street analysts forecast QNCX's earnings for 2026 to be -$185,887,119, with the lowest QNCX earnings forecast at -$243,774,307, and the highest QNCX earnings forecast at -$121,522,017. On average, 4 Wall Street analysts forecast QNCX's earnings for 2027 to be -$174,331,524, with the lowest QNCX earnings forecast at -$261,506,252, and the highest QNCX earnings forecast at -$78,732,574.
In 2028, QNCX is forecast to generate $18,289,430 in earnings, with the lowest earnings forecast at $17,572,198 and the highest earnings forecast at $18,827,355.